233 related articles for article (PubMed ID: 23588953)
1. Characteristics of basal cytokeratin expression in breast cancer.
Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
[TBL] [Abstract][Full Text] [Related]
2. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.
Liu ZB; Wu J; Ping B; Feng LQ; Di GH; Lu JS; Shen KW; Shen ZZ; Shaol ZM
Tumori; 2009; 95(1):53-62. PubMed ID: 19366057
[TBL] [Abstract][Full Text] [Related]
3. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
[TBL] [Abstract][Full Text] [Related]
4. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Lee AH; Ellis IO
Histopathology; 2007 Mar; 50(4):434-8. PubMed ID: 17448018
[TBL] [Abstract][Full Text] [Related]
5. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
7. [Expression of cytokeratins 5/6 and cytokeratin 17 in invasive breast carcinoma].
Ivković-Kapicl T; Panjković M; Nikolić I; Djilas-Ivanović D; Knezević-Usaj S
Vojnosanit Pregl; 2012 Dec; 69(12):1031-8. PubMed ID: 23424955
[TBL] [Abstract][Full Text] [Related]
8. Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer.
McGinn O; Riley D; Finlay-Schultz J; Paul KV; Kabos P; Sartorius CA
Mol Cancer Res; 2022 Sep; 20(9):1443-1455. PubMed ID: 35639459
[TBL] [Abstract][Full Text] [Related]
9. Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast.
Marginean F; Rakha EA; Ho BC; Ellis IO; Lee AH
Mod Pathol; 2010 Oct; 23(10):1357-63. PubMed ID: 20581807
[TBL] [Abstract][Full Text] [Related]
10. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer.
Chen Y; Cui T; Yang L; Mireskandari M; Knoesel T; Zhang Q; Pacyna-Gengelbach M; Petersen I
Oncology; 2011; 80(5-6):333-40. PubMed ID: 21791943
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin.
Dogu GG; Ozkan M; Ozturk F; Dikilitas M; Er O; Ozturk A
Med Oncol; 2010 Mar; 27(1):34-9. PubMed ID: 19156550
[TBL] [Abstract][Full Text] [Related]
14. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
Eerola H; Heinonen M; Heikkilä P; Kilpivaara O; Tamminen A; Aittomäki K; Blomqvist C; Ristimäki A; Nevanlinna H
Breast Cancer Res; 2008; 10(1):R17. PubMed ID: 18275599
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
16. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
Dabbs DJ; Chivukula M; Carter G; Bhargava R
Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.
Martin-Castillo B; Lopez-Bonet E; Buxó M; Dorca J; Tuca-Rodríguez F; Ruano MA; Colomer R; Menendez JA
Oncotarget; 2015 Mar; 6(9):7104-22. PubMed ID: 25742793
[TBL] [Abstract][Full Text] [Related]
18. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.
Sasa M; Bando Y; Takahashi M; Hirose T; Nagao T
J Surg Oncol; 2008 Jan; 97(1):30-4. PubMed ID: 17929254
[TBL] [Abstract][Full Text] [Related]
19. [Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?].
Mainka P; Kahlert S; Kirchner T; Mayr D; Diebold J
Pathologe; 2008 Nov; 29 Suppl 2():363-9. PubMed ID: 18807040
[TBL] [Abstract][Full Text] [Related]
20. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
